One dose of new gene therapy could reduce tau protein throughout brain Voyager Therapeutics’ promising toxicology data in non-human primates suggests their proprietary capsid technology could deliver long-lasting results in Alzheimer’s disease. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/one-dose-of-new-gene-therapy-could-reduce-tau-protein-throughout-brain-17378?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_BaLdDd869QGd4SsxZR5R1pJAcOeDmK92JQ7YaGVGAf2lwIajJ1LGQ9WruBjGC_PCyba5G0svYZbHL6CzzEOP7_4Q_yQ&_hsmi=430295917&utm_content=430295917&utm_source=hs_email Tau-targeting therapies focus on ridding the brain of the toxic tau protein that wreaks havoc in neurodegenerative diseases like Alzheimer’s disease (AD). Drugs currently under investigation to target tau include immunotherapies, small molecule tau inhibitors, antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and gene therapy. Gene therapy options, in particular, have the exciting potential to offer broad and durable reductions in tau in just one dose. How small molecule tau inhibitors could treat Alzheimer’s disease While amyloid plaques form first, new work suggests targeting tau tangles that spread through the brain could also help the fight against this devastating disease. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/how-small-molecule-tau-inhibitors-could-treat-alzheimer-s-disease-16849?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-88Ww_WpM_AZDMP2mK7Fd9gpxGEmaCD-BDQDNvzZbIBw43SSQ8h-P9etgLQHCCneOzKxkLmdgYtJFhdr3HB0GXJjgeCcg&_hsmi=430295917&utm_content=430295917&utm_source=hs_email